Dora Lucia Vallejo Ardila

Dora Lucia Vallejo Ardila

Auto-generated profile, based on publicly available information

Dora Lucia Vallejo Ardila

Foundation for Clinical and Applied Cancer Research—FICMAC, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
DADora Lucia Vallejo Ardila
Dora Lucia Vallejo Ardila
KWKatrina Ann Walsh
Katrina Ann Walsh
TFTheodora Fifis
Theodora Fifis
RPRita Paolini
Rita Paolini
GKGeorgios Kastrappis
Georgios Kastrappis
MPMarcos Vinicius Perini
Marcos Vinicius Perini
Background: It is now recognized that many anticancer treatments positively modulate the antitumor immune response. Clinical and experimental studies have shown that inhibitors of the classical renin–angiotensin system (RAS) reduce tumor progression and are associated with better outcomes in patients with colorectal cancer. RAS components are expressed by most immune cells and adult hematopoietic cells, thus are potential targets for modulating tumor-infiltrating immune cells and can provide a mechanism of tumor control by the renin–angiotensin system inhibitors (RASi). Aim: To investigate the effects of the RASi captopril on tumor T lymphocyte distribution in a mouse model of colorectal liver metastases. Methods: Liver metastases were established in a mouse model using an autologous colorectal cancer cell line. RASi (captopril 750 mg/kg) or carrier (saline) was administered to the mice daily via intraperitoneal injection, from day 1 post-tumor induction to endpoint (day 15 or 21 post-tumor induction). At the endpoint, tumor growth was determined, and lymphocyte infiltration and composition in the tumor and liver tissues were analyzed by flow cytometry and immunohistochemistry (IHC). Results: Captopril significantly decreased tumor viability and impaired metastatic growth. Analysis of infiltrating T cells into liver parenchyma and tumor tissues by IHC and flow cytometry showed that captopril significantly increased the infiltration of CD3+ T cells into both tissues at day 15 following tumor induction. Phenotypical analysis of CD45+ CD3+ T cells indicated that the major contributing phenotype to this influx is a CD4 and CD8 double-negative T cell (DNT) subtype, while CD4+ T cells decreased and CD8+ T cells remained unchanged. Captopril treatment also increased the expression of checkpoint receptor PD-1 on CD8+and DNT subsets . Conclusion: Captopril treatment modulates the immune response by increasing the infiltration and altering the phenotypical composition of T lymphocytes and may be a contributing mechanism for tumor control.

26 October 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
DVDora L. Vallejo-Ardila
Dora L. Vallejo-Ardila
TFTheodora Fifis
Theodora Fifis
LBLouise M. Burrell
Louise M. Burrell
KWKatrina Ann Walsh
Katrina Ann Walsh
CCChristopher Christophi
Christopher Christophi
Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity Renin-angiotensin inhibitors reprogram tumor immune microenvironment: a comprehensive view of the influences on anti-tumor immunity

16 July 2020 in Revista Colombiana de Cardiología
Verified
Journal Article
Open access
DADora Lucía Vallejo Ardila
Dora Lucía Vallejo Ardila
YCYenny Rocío Tamayo Cáceres
Yenny Rocío Tamayo Cáceres
AMAbraham Alí Munive
Abraham Alí Munive
La evidencia actual es limitada para determinar el impacto del uso de los inhibidores de la enzima convertidora de angiotensina (IECA) en la predisposición al empeoramiento de la enfermedad del coronavirus 2019 (COVID-19). Inicialmente se reportó que en los pacientes con progresión grave de la COVID-19 existía una mortalidad elevada, los cuales tenían antecedentes de hipertensión arterial, diabetes mellitus, enfermedad cardiovascular y enfermedad renal crónica. Parte de estos pacientes también tenía en común que utilizaban IECA, lo cual alertó a la comunidad médica sobre su riesgo potencial en coexistencia con COVID-19. Sin embargo, estudios más recientes de casos-controles encontraron que los inhibidores del sistema renina-angiotensina, incluyendo los IECA, no incrementan el riesgo de COVID-19 o de requerir admisión hospitalaria por esta causa. Diferentes revistas científicas han facilitado el acceso a reportes preliminares, dejando a discreción de la comunidad médica y científica hacer uso de dicha información para promover el desarrollo de estudios que confirmen experimentalmente dichos hallazgos, preclínicos y epidemiológicos, que finalmente impacten en las decisiones de la práctica clínica para beneficiar a los pacientes con COVID-19. En esta revisión de la literatura se exploran los diferentes efectos mediados por los IECA que podrían estar relacionados con la respuesta inmune durante la infección y la transmisión de COVID-19, compilando evidencia disponible que evalúa si en realidad representan un riesgo o si, por el contrario, confieren un efecto protector. There is limited evidence for determining the impact of the use of angiotensin converting enzyme inhibitors (ACE-I) in the tendency to worsening of coronavirus-19 disease (COVID-19). It was initially reported that, in patients with serious progression of COVID-19, there was an increased mortality in those that had a history of suffering arterial hypertension, diabetes mellitus, cardiovascular disease, and chronic kidney disease. A proportion of these patients also had in common that they used ACE-I, which alerted the medical community on the potential risk in coexisting with COVID-19. However, in more recent case-control studies, they found that inhibitors of the renin-angiotensin system, including ACE-I, does not increase the risk of COVID-19 or require hospital admission due to this cause. Several scientific journals have provided access to preliminary reports, leaving the use of such information at the discretion of the medical and scientific community for promoting the development of studies that might confirm these preclinical and epidemiological findings experimentally. These may finally have an impact on the clinical practice decisions, in order to benefit patients with COVID-19. In this literature review, the different effects mediated by ACE-I that could be related to the immune response during the infection and transmission of COVID-19 are examined, gathering available evidence that evaluates whether, in reality, they represent a risk or if on the other hand, they confer a protector effect.

1 February 2024 in JCO Global Oncology
Verified
Journal Article
Open access
CSCarolina Sotelo-Rodríguez
Carolina Sotelo-Rodríguez
DVDora Vallejo-Ardila
Dora Vallejo-Ardila
ARAlejandro Ruiz-Patiño
Alejandro Ruiz-Patiño
DCDiego F. Chamorro
Diego F. Chamorro
JRJuly Rodríguez
July Rodríguez
ACAndres Cardona
Andres Cardona
PURPOSE: Multidisciplinary molecular tumor boards (MTBs) decode complex genomic data into clinical recommendations. Although MTBs are well-established in the oncology practice in developed countries, this strategy needs to be better explored in developing countries. Herein, we describe the possible benefits and limitations of the first MTB established in Colombia. METHODS: Demographic, clinical, and genomic information was collected between August 2020 and November 2021. By mid-2020, an MTB strategy was created to discuss clinical cases with one or more genomic alterations identified by next-generation sequencing using an open-access virtual platform. We characterized the patient population as benefiting from the recommended treatment option. We assessed the benefits and access to available targeted therapies that have the potential to change clinical management by making recommendations to treating oncologists on the basis of genomic profiling. However, we did not assess the treatment oncologists' compliance with MTB recommendations because they were not intended to replace clinical judgment/standard of care. RESULTS: A total of 146 patients were included in the discussions of the MTB. The median age was 59 years, and 59.6% were women. Genomic results prompting a change in therapeutic decisions were obtained in 53.1% of patients (95% CI, 44.9 to 61.3). The most prevalent malignancy was non–small-cell lung cancer (51%). Other malignancies represented 60%, 50%, and 30% of patients with soft-tissue sarcomas, brain tumors, and breast cancer, respectively. CONCLUSION: Using an open-access virtual platform, MTBs were feasible in low- and middle-income countries on the basis of the capability to provide the benefits and access to available targeted therapies that are not standard of care. Furthermore, MTB recommendations were made available to the treating oncologist in different locations across Colombia, providing the option to modify clinical management in most of these patients.

10 November 2022 in Revista Colombiana de Cardiología
Verified
Journal Article
Open access
PDF file
MAMaricel L. Ardila
Maricel L. Ardila
LRLesvanny A. Romero
Lesvanny A. Romero
DVDora L. Vallejo-Ardilla
Dora L. Vallejo-Ardilla
La hipertensión arterial se considera como una de las principales causas de morbimortalidad en todo el mundo. Asimismo, su elevada prevalencia en los países en vías de desarrollo se relaciona directamente con el desconocimiento de la enfermedad, e inversamente con la prevalencia del tratamiento y el control de la hipertensión arterial. El objetivo de esta revisión es compilar la evidencia sobre los factores que influencian la prevalencia de conocimiento del diagnóstico de hipertensión arterial, el tratamiento y el control óptimo de la enfermedad dependiendo del contexto epidemiológico. Por ello, se enfatiza que gran parte del desafío en los países en vías de desarrollo consiste en evaluar la escasa evidencia epidemiológica de base poblacional para realizar recomendaciones que se adapten a los recursos disponibles en las diferentes regiones. Para este propósito se realizó una breve revisión sobre las recomendaciones de las guías de práctica clínica propuestas por la Sociedad Internacional de Hipertensión en el año 2020.

5 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
DVDora L. Vallejo-Ardila
Dora L. Vallejo-Ardila
CTCandani S. A. Tutuka
Candani S. A. Tutuka
TFTheodora Fifis
Theodora Fifis
KWKatrina Ann Walsh
Katrina Ann Walsh
VMVijayaragavan Muralidharan
Vijayaragavan Muralidharan
MPMarcos Vinicius Perini
Marcos Vinicius Perini
Colorectal cancer liver metastasis (CLM) is the most of common cause of death in patients with colorectal cancer (CRC) worldwide. There are various immune-suppressive and tumor-promoting mechanisms, which contribute to the unresponsiveness associated with current check point immunotherapy in CRC. Techniques such as Multiplex immunohistochemistry (mIHC) and automated image quantitation analysis, enable a deeper understanding of the diversity of the host’s anti-tumor immune response and could identify potential targets for immunotherapy. Herein, we present a 7-plex OPALTM protocol used to assess the composition and spatial distribution of T cell markers CD3, CD8, Foxp3 and CD103 and the epithelial to mesenchymal transition (EMT) markers alpha smooth muscle actin (α-SMA) and E-cadherin. The protocol has been manually optimized and validated in two independent cohorts of formalin-fixed, paraffin embedded CLM patient tissues (n=42) using well-established antibodies, single spectral library, negative controls and biological controls for corroborating staining pattern of α-SMA+ (sclerosed hemangioma samples) and T-cell infiltrates (benign liver). The accurate profiling of T- cell composition, location and phenotypic characterization could reveal important insights about the influence of T lymphocytes on prognosis after liver metastasectomy.